We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Human CRP-Levels Compared Using Point-of-Care Methods

By LabMedica International staff writers
Posted on 08 Oct 2019
Due to the rapid increase of the C-reactive protein (CRP) concentration in the event of an inflammatory disease, CRP is regarded as one of the most important acute phase proteins. More...
Inflammation and CRP play an important role in operations, trauma, mental stress, myocardial infarction and neoplastic diseases.

The use of point-of-care (POC) methods and the measurements of CRP as a diagnostic marker have both increased over the past years. This has led to an increase in POC-methods analyzing CRP. High CRP levels are often seen as an indication for the proscribing of antibiotics. The quality of POC-systems compared to routine diagnostic measurements for the analysis of CRP is thereby of major importance, since many small practices will use POC-methods.

Biomedical scientists from the Salzburg University of Applied Sciences (Puch bei Hallein, Austria) compared POC and classical clinical chemistry methods, using 199 anonymized patient samples (104 male and 95 female patients aged from 31 to 96 years). The blood samples were selected based on a CRP concentration of more than 100 mg/L as measured by the Architect ci8200SR.

Comparisons were then made with ABX Micros CRP 200 (Horiba, Kyoto, Japan) and the i-CHROMA system. The CRP-levels on the Architect ci8200 were detected using serum samples and the method is based on a turbidimetric assay. EDTA-whole blood was used for the test procedure with the i-CHROMA and ABX. The ABX also works with a turbidimetric assay system and the i-CHROMA is based on a fluorescence sandwich immunoassay. The values from the i-CHROMA were used corrected for the hematocrit values.

The scientists reported that the results of the Architect ci8200 and the ABX showed significant differences when compared to the results of the i-CHROMA with hematocrit corrections. In addition, the values of the Architect ci8200 and the ABXs were also significantly different. Nevertheless, the most pronounced differences were seen when comparing the i-CHROMA with the Architect ci8200 with detected differences of up to 147.6 mg/L. Comparing the values of the i-CHROMA with the ABX resulted in differences of up to 92.7 mg/L. The lowest maximal difference of 39.4 mg/L is seen when comparing the results of the Architect ci8200 and the ABX.

The authors concluded that the measured CRP concentrations of the i-CHROMA strongly differ in the higher CRP concentration range when compared to the measurements performed on routine diagnostic equipment. The significantly reduced CRP measurements can strongly affect patient safety and result in wrong diagnostic measures. The study was published on September 19, 2019, in the journal Practical Laboratory Medicine.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Whole Blood Control
Lyphochek Whole Blood Control
New
See-Saw Rocking Shaker
SH-200D-S-L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: A new at-home self-collection device aims to reduce the screening gap for cervical cancer (Photo courtesy of CU School of Medicine)

New At-Home Cervical Cancer Screening Device to Increase Accessibility for Patients

Cervical cancer is typically linked to certain types of human papillomavirus (HPV), which is passed through sexual contact. While many people are infected with HPV, only a small percentage will develop... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.